These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 832522)

  • 21. Fosfomycin in treatment of respiratory bacterial infections.
    Bonora V; Lozano C; Santos M; Paz M; Baguena J; Gobernado M
    Chemotherapy; 1977; 23 Suppl 1():337-41. PubMed ID: 832534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
    Wilson DT; May DB
    Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical trial of fosfomycin for Campylobacter enteritis].
    Nogawa T; Takeuchi Y; Watanabe J; Kimura K; Tomii I; Abe T; Watanabe Y; Nakasone K; Fujimori I; Kobayashi Y
    Jpn J Antibiot; 1984 Sep; 37(9):1620-4. PubMed ID: 6512981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical experience with fosfomycin sodium for bacterial infections in obstetrics and gynecology].
    Yamamoto T; Yasuda J; Kanao M; Okada H
    Jpn J Antibiot; 1983 Aug; 36(8):2109-14. PubMed ID: 6655828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The role of fosfomycin in the management of urinary tract infections].
    Zaitsev AV; Kolontarev KB
    Urologiia; 2017 Sep; (4):91-96. PubMed ID: 28952700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical experience with fosfomycin in urinary tract infections (author's transl)].
    Peters HJ; Eicher R
    MMW Munch Med Wochenschr; 1981 May; 123(18):748-50. PubMed ID: 6785627
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overview of clinical experience with ciprofloxacin.
    Ball AP
    Eur J Clin Microbiol; 1986 Apr; 5(2):214-9. PubMed ID: 3013631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical evaluation of the combination of carumonam and fosfomycin in the treatment of complicated urinary tract infection].
    Kakizaki H; Ishii N; Murakami S; Suzuki K; Takamizawa A; Hirano J; Mitobe K; Saito M; Hirano K; Imamura A
    Hinyokika Kiyo; 1990 Jun; 36(6):731-5. PubMed ID: 2239570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of respiratory infections with fosfomycin.
    Bacardí R; Tornos J; Moga I; Martí N; Alomar P; Gaztelurrutia L; Villalonga C
    Chemotherapy; 1977; 23 Suppl 1():343-7. PubMed ID: 832535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Fosfomycin--its significance for treatment of diseases due to multidrug-resistant bacteria].
    Stock I
    Med Monatsschr Pharm; 2015 Jan; 38(1):4-11. PubMed ID: 26349119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs.
    Grayson ML; Macesic N; Trevillyan J; Ellis AG; Zeglinski PT; Hewitt NH; Gardiner BJ; Frauman AG
    Clin Infect Dis; 2015 Oct; 61(7):1141-3. PubMed ID: 26063723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of norfloxacin in the pediatric field. Pediatric Study Group for Norfloxacin].
    Fujii R; Meguro H; Arimasu O; Ushijima K; Abe T; Nakazawa S; Sato H; Narita A; Niino K; Ichihashi H
    Jpn J Antibiot; 1990 Jan; 43(1):181-215. PubMed ID: 2190014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A reappraisal of current dosing strategies for intravenous fosfomycin in children and neonates.
    Traunmüller F; Popovic M; Konz KH; Vavken P; Leithner A; Joukhadar C
    Clin Pharmacokinet; 2011 Aug; 50(8):493-503. PubMed ID: 21740073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical evaluation of high dose intravenous injection of fosfomycin on the severe infections associated with the treatment of haematological disorders].
    Ueda T; Masaoka T; Shibata H; Nagai K; Kanamaru A; Horiuchi A; Hasegawa H; Kitani T; Taniguchi N; Yonezawa T; Tsubakio T; Kawagoe H; Shinohara Y
    Jpn J Antibiot; 1983 Feb; 36(2):311-5. PubMed ID: 6854939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of Monuril in lower urinary tract infections due to fosfomycin-resistant bacteria.
    Neuman M; Rufin F
    Eur Urol; 1987; 13 Suppl 1():105-7. PubMed ID: 3552693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections.
    Roussos N; Karageorgopoulos DE; Samonis G; Falagas ME
    Int J Antimicrob Agents; 2009 Dec; 34(6):506-15. PubMed ID: 19828298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of urinary infections with fosfomycin.
    Neuman M; Fluteau G
    Chemotherapy; 1977; 23 Suppl 1():259-64. PubMed ID: 832524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of recurrent complicated urinary tract infections in children with vesicoureteral reflux.
    Wu TH; Huang FL; Fu LS; Chou CM; Chien YL; Huang CM; Lin CF; Chen PY
    J Microbiol Immunol Infect; 2016 Oct; 49(5):717-722. PubMed ID: 25442872
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical chemotherapeutic evaluation of fosfomycin plus amoxicillin (co-fosfolactamine): a prospective double-blind clinical trial.
    Novelli A; Rizzo M; Buzzoni P; Coronnello M; Alunno Pergentini S; Giganti E; Periti P
    Chemioterapia; 1984 Oct; 3(5):281-5. PubMed ID: 6398125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.